Walensky Defends Decision To Go Against Advisors On Pfizer COVID Booster Recommendation
‘If I had been in the room, I would have voted yes,’ CDC director says of ACIP. ‘This was a scientific close call. ... And that was how my recommendations came out after listening to all of their scientific deliberations.’
You may also be interested in...
US CDC Panel Supports Moderna, Janssen COVID Vaccine Boosters But Strips Out Preference Language For Homologous Dosing
ACIP pushes back on proposed policy recommendation that the same product used for the primary regimen should be used for the booster, saying risk/benefit and other considerations necessitate more flexibility afforded by 'mix and match' approach.
Immune responses to a single booster dose of mRNA-1273 would be considered successfully bridged to the two-dose primary series if each of two immunobridging criteria were met, but the mRNA vaccine missed the prespecified success criteria for seroresponse rate, the FDA said.
Federal government needs to make sure its messaging on vaccines is harmonized, CBER director Marks says. Vaccine development could have been accelerated in pregnant, pediatric and immunocompromised populations, he notes.